252 related articles for article (PubMed ID: 31785343)
41. [The role of inhaled steroids in the treatment of COPD].
Ställberg B; Janson C; Lindén A; Lisspers K; Larsson K
Lakartidningen; 2020 Oct; 117():. PubMed ID: 33107583
[TBL] [Abstract][Full Text] [Related]
42. Intensified Therapy with Inhaled Corticosteroids and Long-Acting β
Stolz D; Hirsch HH; Schilter D; Louis R; Rakic J; Boeck L; Papakonstantinou E; Schindler C; Grize L; Tamm M
Am J Respir Crit Care Med; 2018 May; 197(9):1136-1146. PubMed ID: 29266965
[TBL] [Abstract][Full Text] [Related]
43. Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β
Skolnik NS; Nguyen TS; Shrestha A; Ray R; Corbridge TC; Brunton SA
Postgrad Med; 2020 Mar; 132(2):198-205. PubMed ID: 31900019
[TBL] [Abstract][Full Text] [Related]
44. Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO).
Rossi A; Guerriero M; Corrado A;
Respir Res; 2014 Jul; 15(1):77. PubMed ID: 25005873
[TBL] [Abstract][Full Text] [Related]
45. Use of ICS in COPD: From Blockbuster Medicine to Precision Medicine.
Contoli M; Corsico AG; Santus P; Di Marco F; Braido F; Rogliani P; Calzetta L; Scichilone N
COPD; 2017 Dec; 14(6):641-647. PubMed ID: 29116901
[TBL] [Abstract][Full Text] [Related]
46. Impact of smoking status and concomitant medications on the effect of high-dose N-acetylcysteine on chronic obstructive pulmonary disease exacerbations: A post-hoc analysis of the PANTHEON study.
Papi A; Zheng J; Criner GJ; Fabbri LM; Calverley PMA
Respir Med; 2019 Feb; 147():37-43. PubMed ID: 30704697
[TBL] [Abstract][Full Text] [Related]
47. First maintenance therapy for COPD in the UK between 2009 and 2012: a retrospective database analysis.
Price D; Miravitlles M; Pavord I; Thomas M; Wedzicha J; Haughney J; Bichel K; West D
NPJ Prim Care Respir Med; 2016 Nov; 26():16061. PubMed ID: 27808096
[TBL] [Abstract][Full Text] [Related]
48. Inhaled Corticosteroids in Subjects with Chronic Obstructive Pulmonary Disease: An Old, Unfinished History.
Melani AS; Croce S; Fabbri G; Messina M; Bargagli E
Biomolecules; 2024 Feb; 14(2):. PubMed ID: 38397432
[TBL] [Abstract][Full Text] [Related]
49. Inhaled corticosteroids in COPD: the clinical evidence.
Ernst P; Saad N; Suissa S
Eur Respir J; 2015 Feb; 45(2):525-37. PubMed ID: 25537556
[TBL] [Abstract][Full Text] [Related]
50. Inhaled corticosteroids do not adversely impact outcomes in COVID-19 positive patients with COPD: An analysis of Cleveland Clinic's COVID-19 registry.
Sen P; Majumdar U; Zein J; Hatipoğlu U; Attaway AH
PLoS One; 2021; 16(6):e0252576. PubMed ID: 34081722
[TBL] [Abstract][Full Text] [Related]
51. Stability of the Blood Eosinophilic Phenotype in Stable and Exacerbated COPD.
Schumann DM; Tamm M; Kostikas K; Stolz D
Chest; 2019 Sep; 156(3):456-465. PubMed ID: 31047957
[TBL] [Abstract][Full Text] [Related]
52. Sputum inflammation predicts exacerbations after cessation of inhaled corticosteroids in COPD.
Liesker JJ; Bathoorn E; Postma DS; Vonk JM; Timens W; Kerstjens HA
Respir Med; 2011 Dec; 105(12):1853-60. PubMed ID: 21802933
[TBL] [Abstract][Full Text] [Related]
53. Inhaled corticosteroids in chronic obstructive pulmonary disease and risk of death and hospitalization: time-dependent analysis.
Fan VS; Bryson CL; Curtis JR; Fihn SD; Bridevaux PO; McDonell MB; Au DH
Am J Respir Crit Care Med; 2003 Dec; 168(12):1488-94. PubMed ID: 14525798
[TBL] [Abstract][Full Text] [Related]
54. Inhaled Corticosteroid Use Among COPD Patients in Primary Care in Spain.
Miravitlles M; Roman-Rodríguez M; Ribera X; Ritz J; Izquierdo JL;
Int J Chron Obstruct Pulmon Dis; 2022; 17():245-258. PubMed ID: 35115771
[TBL] [Abstract][Full Text] [Related]
55. Association between COPD exacerbations and lung function decline during maintenance therapy.
Kerkhof M; Voorham J; Dorinsky P; Cabrera C; Darken P; Kocks JW; Sadatsafavi M; Sin DD; Carter V; Price DB
Thorax; 2020 Sep; 75(9):744-753. PubMed ID: 32532852
[TBL] [Abstract][Full Text] [Related]
56. Inhaled corticosteroids and survival in COPD patients receiving long-term home oxygen therapy.
Tkacova R; Toth S; Sin DD
Respir Med; 2006 Mar; 100(3):385-92. PubMed ID: 16105731
[TBL] [Abstract][Full Text] [Related]
57. Reported pneumonia in patients with COPD: findings from the INSPIRE study.
Calverley PMA; Stockley RA; Seemungal TAR; Hagan G; Willits LR; Riley JH; Wedzicha JA;
Chest; 2011 Mar; 139(3):505-512. PubMed ID: 20576732
[TBL] [Abstract][Full Text] [Related]
58. Oral Low-dose Theophylline on Top of Inhaled Fluticasone-Salmeterol Does Not Reduce Exacerbations in Patients With Severe COPD: A Pilot Clinical Trial.
Cosío BG; Shafiek H; Iglesias A; Yanez A; Córdova R; Palou A; Rodriguez-Roisin R; Peces-Barba G; Pascual S; Gea J; Sibila O; Barnes PJ; Agusti A
Chest; 2016 Jul; 150(1):123-30. PubMed ID: 27107490
[TBL] [Abstract][Full Text] [Related]
59. Factors associated with inhaled corticosteroids prescription in primary care patients with COPD: A cross-sectional study in the Balearic Islands (Spain).
Román-Rodríguez M; van Boven JF; Vargas F; Contreras CC; Lamelas G; Gestoso S; Góngora M; Corredor M; Esteva M
Eur J Gen Pract; 2016 Dec; 22(4):232-239. PubMed ID: 27597172
[TBL] [Abstract][Full Text] [Related]
60. Inhaled Corticosteroid Withdrawal and Change in Lung Function in Primary Care Patients with Chronic Obstructive Pulmonary Disease in England.
Whittaker HR; Wing K; Douglas I; Kiddle SJ; Quint JK
Ann Am Thorac Soc; 2022 Nov; 19(11):1834-1841. PubMed ID: 35767034
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
